Indobufen-based dual antiplatelet therapy in patients undergoing PCI: a systematic review and meta-analysis

BackgroundConventional dual antiplatelet therapy (DAPT) post percutaneous coronary intervention (PCI) comprises aspirin and a P2Y12 inhibitor. However, aspirin increases gastrointestinal and bleeding risks. Indobufen, a reversible COX-1 inhibitor, may offer a safer alternative.ObjectivesTo evaluate...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yiheng Liu, Bin Liu, Weiran Dai
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-07-01
Edice:	Frontiers in Pharmacology
Témata:	aspirin cardiovascular outcomes dual antiplatelet therapy indobufen major adverse cardiac events meta-analysis
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1821883/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!